MGMT and glioblastoma: Pioneering umbrella trials such as the N2M2 phase I/II or the INSIGhT phase II studies, which both explore the efficacy of molecularly informed therapeutic strategies in selected patients with glioblastoma without hypermethylation of the promotor of the O-6-methylguanine-DNA methyltransferase (MGMT), represent a significant stride towards this direction31,32.